Bavarian sees results of Phase III Prostvac trial by early 2017

COPENHAGEN (Reuters) - Bavarian Nordic expects the full results of its Phase III trials for prostate cancer drug Prostvac by early 2017, Chief Executive Paul Chaplin said after the Danish firm struck a $1 billion supply deal with Bristol-Myers Squibb. "We're looking at late 2016, early 2017 based on potential full data readout," he said when asked when the results could come. "There are pre-interim analyses that have been agreed with the FDA (U.S. Food and Drugs Administration). ...



via Health News Headlines - Yahoo News http://ift.tt/1AHQ50H